VAERS Table of Reportable Events Following Vaccination
https://vaers.hhs.gov/index
VAERS Table of Reportable Events Following Vaccination*
Vaccine/Toxoid Event and interval from vaccination
Tetanus in any combination; DTaP, DTP, DTP-Hib,
DT, Td, TT, Tdap, DTaP-IPV, DTaP-IPV/Hib, DTaPHepB-
IPV
A. Anaphylaxis or anaphylactic shock (7 days)
B. Brachial neuritis (28 days)
C. Any acute complications or sequelae (including death)
of above events (interval – not applicable)
D. Events described in manufacturer’s package insert as
contraindications to additional doses of vaccine (interval
– see package insert)
Pertussis in any combination; DTaP, DTP, DTPHib,
Tdap, P, DTaP-IPV, DTaP-IPV/Hib, DTaPHepB-
IPV
A. Anaphylaxis or anaphylactic shock (7 days)
B. Encephalopathy or encephalitis (7 days)
C. Any acute complications or sequelae (including death)
of above events (interval – not applicable)
D.
Events described in manufacturer’s package insert as
contraindications to additional doses of vaccine (interval
– see package insert)
Measles, mumps and rubella in any combination;
MMR, MR, M, MMRV, R
A. Anaphylaxis or anaphylactic shock (7 days)
B. Encephalopathy or encephalitis (15 days)
C. Any acute complications or sequelae (including death)
of above events (interval – not applicable)
D. Events described in manufacturer’s package insert as
contraindications to additional doses of vaccine (interval
– see package insert)
Rubella in any combination; MMR, MMRV, MR, R
A. Chronic arthritis (42 days)
B. Any acute complications or sequelae (including death)
of above event (interval – not applicable)
C. Events described in manufacturer’s package insert as
contraindications to additional doses of vaccine (interval
– see package insert)
Measles in any combination; MMR, MMRV, MR, M
A. Thrombocytopenic purpura (7-30 days)
B. Vaccine-strain measles viral infection in an
immunodeficient recipient (6 months)
C. Any acute complications or sequelae (including death)
of above events (interval – not applicable)
D. Events described in manufacturer’s package insert as
contraindications to additional doses of vaccine (interval
– see package insert)
Oral Polio (OPV)
A. Paralytic polio
o
in a non-immunodeficient recipient (30 days)
o
in an immunodeficient recipient (6 months)
o
in a vaccine-associated community case
(interval – not applicable)
B. Vaccine-strain polio viral infection
o
in a non-immunodeficient recipient (30 days)
o
in an immunodeficient recipient (6 months)
VAERS Table of Reportable Events Following Vaccination*
Vaccine/Toxoid Event and interval from vaccination
o
in a vaccine-associated community case
(interval – not applicable)
C. Any acute complication or sequelae (including death) of
above events (interval – not applicable)
D. Events described in manufacturer’s package insert as
contraindications to additional doses of vaccine (interval
– see package insert)
Inactivated Polio -IPV, DTaP-IPV, DTaP-IPV/HIB,
DTaP-HepB-IPV
A. Anaphylaxis or anaphylactic shock (7 days)
B. Any acute complication or sequelae (including death) of
the above event (interval – not applicable)
C. Events described in manufacturer’s package insert as
contraindications to additional doses of vaccine (interval
– see package insert)
Hepatitis B in any combination- HepB, HepAHepB,
DTaP-HepB-IPV, Hib-HepB
A. Anaphylaxis or anaphylactic shock (7 days)
B. Any acute complications or sequelae (including death)
of the above event (interval – not applicable)
C. Events described in manufacturer’s package insert as
contraindications to additional doses of vaccine (interval
– see package insert)
Hemophilus influenzae
type b in any combination
(conjugate)- Hib, Hib-HepB, DTP-Hib, DTaPIPV/
Hib
Events described in manufacturer’s package insert as
contraindications to additional doses of vaccine (interval – see
package insert)
Varicella in any combination- VAR, MMRV
Events described in manufacturer’s package insert as
contraindications to additional doses of vaccine (interval – see
package insert)
Rotavirus (monovalent or pentavalent) RV1, RV5
Events described in manufacturer’s package insert as
contraindications to additional doses of vaccine (interval – see
package insert)
Pneumococcal conjugate (7-valent or 13-valent)
PCV7, PCV13
Events described in manufacturer’s package insert as
contraindications to additional doses of vaccine (interval – see
package insert)
Hepatitis A in any combination- HepA, HepA-HepB
Events described in manufacturer’s package insert as
contraindications to additional doses of vaccine (interval – see
package insert)
Influenza–t
rivalent inactivated influenza , live
Events described in manufacturer’s package insert as
contraindications to additional doses of vaccine (interval – see
package insert)
VAERS Table of Reportable Events Following Vaccination*
Vaccine/Toxoid Event and interval from vaccination
attenuated influenza
‐TIV, LAIV
Meningococcal – MCV4, MPSV4
Events described in manufacturer’s package insert as
contraindications to additional doses of vaccine (interval – see
package insert)
Human Papillomavirus (Quadrivalent or Bivalent)-
HPV4, HPV2
Events described in manufacturer’s package insert as
contraindications to additional doses of vaccine (interval – see
package insert)
* Effective date: November 10, 2008
. The Reportable Events Table (RET) reflects what is reportable by law (42 USC
300aa-25) to the Vaccine Adverse Event Reporting System (VAERS) including conditions found in the manufacturers
package insert. In addition, healthcare professionals are encouraged to report any clinically significant or unexpected
events (even if you are not certain the vaccine caused the event) for any vaccine, whether or not it is listed on the RET.
Manufacturers are also required by regulation (21CFR 600.80) to report to the VAERS program all adverse events made
known to them for any vaccine.
A list of vaccine abbreviations is attached and is also located at:
http://www.cdc.gov/vaccines/recs/acip/vac
‐abbrev.htm
Vaccine Abbreviation
*
Diphtheria and tetanus toxoids adsorbed (children) DT
Diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed DTaP
Diphtheria and tetanus toxoids and whole cell pertussis vaccine DTP
Diphtheria and tetanus toxoids and whole cell pertussis vaccine and
Haemophilus influenzae type
b conjugate vaccine
DTP-Hib
Tetanus and diphtheria toxoids adsorbed (adult) Td
Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed Tdap
Tetanus toxoid TT
Diphtheria and tetanus toxoids and acellular pertussis adsorbed and
Haemophilus influenzae type
b conjugate vaccine
DTaP/Hib
Diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B and inactivated
poliovirus vaccine
DTaP-HepBIPV
Diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine DTaP-IPV
Diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and
Haemophilus influenzae
type b conjugate vaccine
DTaP-IPV/Hib
Haemophilus influenzae
type b conjugate vaccine Hib
Haemophilus influenzae
type b conjugate and hepatitis B vaccine Hib-HepB
Hepatitis A vaccine
HepA
Hepatitis B vaccine
HepB
Hepatitis A inactivated and hepatitis B vaccine
HepA-HepB
Human papillomavirus vaccine (quadrivalent)
HPV4
Human papillomavirus vaccine (bivalent)
HPV2
Trivalent inactivated influenza vaccine
TIV
Live attenuated influenza vaccine
LAIV
Measles vaccine
M
Measles and rubella vaccine
MR
Measles, mumps, and rubella vaccine MMR
Measles, mumps, rubella, and varicella vaccine
MMRV
Meningococcal conjugate vaccine (quadrivalent)
MCV4
Meningococcal polysaccharide vaccine (quadrivalent)
MPSV4
Pertussis
P
Pneumococcal conjugate vaccine (7-valent)
PCV7
Pneumococcal conjugate vaccine (13-valent)
PCV13
Poliovirus vaccine (inactivated)
IPV
Poliovirus vaccine (live)
OPV
Rubella vaccine
R
Rotavirus vaccine (monovalent)
RV1
Rotavirus vaccine (pentavalent)
RV5
Varicella vaccine
VAR
*dash (-) indicates: products that are supplied in their final form by the manufacturer and do not require
mixing or reconstitution by user; slash ( / ) indicates: products that are mixed or reconstituted by user.
the news network 